Heart Failure: key endpoint results by drug
The key endpoints of Heart Failure trials, with each approved or late-stage drug's result from its own trial: the lead dose against placebo (or the trial's active comparator), the week, and the arm size. These are the same rows as the drug comparison, for every drug at once. To set chosen drugs side by side, with every shared endpoint, use the comparison. The drug list and pipeline are on the Heart Failure page.
CV death or HF hospitalisation
| Drug | Result | Control | Difference | Dose · week · n | Trial |
|---|---|---|---|---|---|
| Dapagliflozin | 16.1% | 20.9% | −4.8 | 10 mg · n 2373 | NCT03036124 Phase 3, secondary |
| Ivabradine | 24.5% | 28.7% | −4.2 | n 3241 | NCT02441218 Phase 3, primary |
| Omecamtiv mecarbil | 37% | 39.1% | −2.1 | n 4120 | NCT02929329 Phase 3, primary |
| Sacubitril/valsartan | 10.9% | 11.8% (Ramipril) | — | n 2830 | NCT02924727 Phase 3, secondary |
Drugs checked with no result here: 14 trial running, 14 not reported, 10 not posted.
HF hospitalisation
| Drug | Result | Control | Difference | Dose · week · n | Trial |
|---|---|---|---|---|---|
| Empagliflozin | 5.3% | 4.5% | +0.8 | 10 mg · n 265 | NCT04157751 Phase 3, secondary |
| Ferric carboxymaltose | 25.4% | 32.4% | −7 | wk 52 · n 558 | NCT02937454 Phase 4, secondary |
| Ivabradine | 15.9% | 20.6% | −4.7 | n 3241 | NCT02441218 Phase 3, secondary |
| Omecamtiv mecarbil | 27.7% | 28.7% | −1 | n 4120 | NCT02929329 Phase 3, secondary |
| Sacubitril/valsartan | 22.1% | 24.1% (Enalapril) | — | n 462 | NCT04023227 Phase 4, primary |
Drugs checked with no result here: 14 trial running, 14 not reported, 9 not posted.
CV death
| Drug | Result | Control | Difference | Dose · week · n | Trial |
|---|---|---|---|---|---|
| Dapagliflozin | 7.4% | 8.3% | −0.9 | 10 mg · n 3131 | NCT03619213 Phase 3, secondary |
| Ivabradine | 13.9% | 15% | −1.1 | n 3241 | NCT02441218 Phase 3, secondary |
| Omecamtiv mecarbil | 19.6% | 19.4% | +0.2 | n 4120 | NCT02929329 Phase 3, secondary |
| Sacubitril/valsartan | 23.8% | 25.4% (Enalapril) | — | n 462 | NCT04023227 Phase 4, primary |
Drugs checked with no result here: 14 trial running, 14 not reported, 10 not posted.
KCCQ clinical summary, change
| Drug | Result | Control | Difference | Dose · week · n | Trial |
|---|---|---|---|---|---|
| Dapagliflozin | 68.6 | 62.8 | +5.8 | wk 12 · n 162 | NCT03030235 Phase 4, primary |
| Empagliflozin | 4.5 | 3.2 | +1.3 | 10 mg · wk 52 · n 2333 | NCT03057951 Phase 3, secondary |
| Finerenone | 21.3 | 24.3 (Eplerenone) | — | 2.5-5 mg OD · wk 12.86 · n 161 | NCT01807221 Phase 2, secondary |
| Sacubitril/valsartan | -1.5 | -2.5 (Valsartan) | — | wk 32 · n 2407 | NCT01920711 Phase 3, secondary |
Drugs checked with no result here: 14 trial running, 15 not reported, 9 not posted.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- Rows are in drug-name order, not ranked. Difference is the lead arm minus placebo, in the endpoint's unit. 42 approved or late-stage drugs with a featured trial in Heart Failure were checked; results come from ClinicalTrials.gov posted results unless marked. Updated 2026-11-20. How results are chosen: methodology.